Interactions

Displaying 201 - 400 of 1240

ARV

Drug 2

Color Code

Drug 1 dose (field_drug_1_dose)

Drug doses

ID	Title	drug 1 Sort descending	drug 1 dose	drug 1 effect	drug 2	drug 2 dose	drug 2 effect	Clinical Effects	Color	Clinical Bottom Line	Management	Alt Agents	Info Source
6080	Efavirenz SOF/VEL 465	Efavirenz			Sofosbuvir / Velpatasvir / Voxilaprevir		Velpatasvir Cmax decreased 37%; AUC decreased 43%; Cmin decreased 47%	Reduced levels of velapatasvir and voxilaprevir	Red: Avoid combination	Do not coadminister: Reduced levels of velpatasvir and voxilapervir	Contraindicated. Use alternative agents.
6096	Efavirenz Ketoconazole 481	Efavirenz			Ketoconazole		Not studied (may decrease ketoconazole levels)	Decreased ketoconazole effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination and use alternative agents
6112	Efavirenz Clarithromycin 497	Efavirenz	400 mg x 7 days	No significant change	Clarithromycin	500 mg Q12H x 7 days	Clarithromycin AUC decreased 39%; Cmax decreased 26%;14-hydroxy clarithromycin AUC increased 34%; Cmax increased 49%	Risk of QT interval prolongation	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Dose adjustment not established. Monitor for antbiotic efficacy and / or consider using alternative agents
5985	Efavirenz Pravastatin 370	Efavirenz	600 mg daily on days 4-18	No significant change	Pravastatin	40 mg daily on days 0-3 and 15-18	Pravastatin AUC decreased 40%	Decreased lipid effects	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of pravastatin	Monitor statin efficacy. May need to increase pravastatin dose
6001	Efavirenz Voriconazole 386	Efavirenz	300 mg QHS x 7 days	Efavirenz AUC increased 17%; Cmax no significant change	Voriconazole	400 mg Q12H on days 2-7	Voriconazole Cmax increased 23%		Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of voriconazole and increased levels of efavirenz	Increase voriconazole to 400 mg Q12H and decrease efavirenz to 300 mg QHS
6017	Efavirenz Sertraline 402	Efavirenz	600 mg daily x 14 days		Sertraline	50 mg daily x 14 days	Sertaline decreased 39%, Cmax decreased 29%, Cmin decreased 46%	Decreased sertaline effects	Green: Administer standard doses	Administer standard doses	Monitor for signs and symptoms of depression and titrate sertaline to effect
6033	Efavirenz Z-Pak 418	Efavirenz	400 mg x 7 days	No significant change	Azithromycin	600 mg x 1 dose	Azithromycin AUC no significant change; Cmax increased 22%		Green: Administer standard doses	Administer standard doses
6049	Efavirenz ATV 434	Efavirenz	600 mg daily days 7-20		Atazanavir	400 mg daily x 20 days	Atazanavir AUC decreased 74%, Cmax decreased 59%, Cmin decreased 93%.	Potential loss of antiviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Use alternative agents
6065	Efavirenz G/P 450	Efavirenz			Glecaprevir / Pibrentasvir			Possible decrease in glecaprevir and pribrentasvir levels	Red: Avoid combination	Do not coadminister: Reduced levels of glecaprevir / pibrentasvir	contraindicated. Use alternative agents.
6081	Efavirenz SOF/VEL 466	Efavirenz			Sofosbuvir / Velpatasvir / Voxilaprevir		Velpatasvir Cmax decreased 37%; AUC decreased 43%; Cmin decreased 47%	Reduced levels of velapatasvir and voxilaprevir	Red: Avoid combination	Do not coadminister: Reduced levels of velpatasvir and voxilapervir	Contraindicated. Use alternative agents.
6097	Efavirenz Triazolam 482	Efavirenz		Not studied	Triazolam		Not studied (may increase triazolam levels)	Increased triazolam effects (eg, increased sedation, confusion, respiratory depression)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination and use alternative agents	Lorazepam, Oxazepam, Temazepam, Trazodone
6113	Efavirenz Clarithromycin 498	Efavirenz	400 mg x 7 days	No significant change	Clarithromycin	500 mg Q12H x 7 days	Clarithromycin AUC decreased 39%; Cmax decreased 26%;14-hydroxy clarithromycin AUC increased 34%; Cmax increased 49%	Risk of QT interval prolongation	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Dose adjustment not established. Monitor for antbiotic efficacy and / or consider using alternative agents
5986	Efavirenz Pravastatin 371	Efavirenz	600 mg daily x 15 days	No significant change	Pravastatin	40 mg daily x 4 days	Pravastatin AUC decreased 44%; Cmax decreased 32%; Cmin decreased 19%	Decreased pravastatin effects	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of pravastatin	Monitor statin efficacy. May need to increase pravastatin dose
6002	Efavirenz Voriconazole 387	Efavirenz	300 mg QHS x 7 days	Efavirenz AUC increased 17%; Cmax no significant change	Voriconazole	400 mg Q12H on days 2-7	Voriconazole Cmax increased 23%		Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of voriconazole and increased levels of efavirenz	Increase voriconazole to 400 mg Q12H and decrease efavirenz to 300 mg QHS
6018	Efavirenz Sertraline 403	Efavirenz	600 mg daily x 14 days		Sertraline	50 mg daily x 14 days		Decreased sertaline effects	Green: Administer standard doses	Administer standard doses	Monitor for signs and symptoms of depression and titrate sertaline to effect
6034	Efavirenz Cetirizine 419	Efavirenz	600 mg x 10 days	No significant change	Cetirizine	10 mg x 1 dose	Cetirizine Cmax decreased 24%		Green: Administer standard doses	Administer standard doses
6050	Efavirenz ATV 435	Efavirenz	600 mg daily days 7-20		Atazanavir	400 mg daily x 20 days	Atazanavir AUC decreased 74%, Cmax decreased 59%, Cmin decreased 93%.	Potential loss of antiviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Use alternative agents
6066	Efavirenz LNG 451	Efavirenz	600 mg QHS		Levonorgestrel	0.75 mg x 1	Levonorgestrel AUC decreased 64%; Cmax decreased 45%; Cmin decreased 71%; half-life: decreased 47%	Decreased levonorgestrel effects	Red: Avoid combination	Do not coadminister: Reduced levels of levonorgestrel	Use alternative contraceptive method
6082	Efavirenz SOF/VEL 467	Efavirenz			Sofosbuvir / Velpatasvir / Voxilaprevir		Velpatasvir Cmax decreased 37%; AUC decreased 43%; Cmin decreased 47%	Reduced levels of velapatasvir and voxilaprevir	Red: Avoid combination	Do not coadminister: Reduced levels of velpatasvir and voxilapervir	Contraindicated. Use alternative agents.
6098	Efavirenz Clopidogrel 483	Efavirenz			Clopidogrel			Possible decreased activation of clopidogrel	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination and use alternative agents
6114	Efavirenz Warfarin 499	Efavirenz		Not studied	Warfarin		Not studied (may increase or decrease warfarin levels)	Increased or decreased warfarin effects (altered INR, increased risk of bleeding or clotting)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering monitor INR and adjust warfarin as indicated. Monitor for signs and symptons of bleeding.
5987	Efavirenz RFB 372	Efavirenz	600 mg x 14 days	No significant change	Rifabutin	300 mg daily x 14 days	Rifabutin AUC decreased 38%; Cmax decreased 32%	Decreased rifabutin effects	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of rifabutin	Increase rifabutin to 450-600 mg daily. May use rifabutin 300 mg three times weekly if not coadministered with a protease inhibitor
6003	Efavirenz Diltiazem 388	Efavirenz	600 mg daily x 14 days	No significant change	Diltiazem	240 mg daily x 21 days	Diltiazem AUC decreased 69%; Cmax decreased 60%; Cmin decreased 63%	Decreased diltiazem effects	Green: Administer standard doses	Administer standard doses	Monitor diltiazem efficacy and to titrate to clinical effect
6019	Efavirenz Buprenorphine / naloxone 404	Efavirenz	600 mg daily x 15 days	No significant change	Buprenorphine / naloxone	stable dose for at least 2 weeks	Buprenorphine AUC decreased 49%; Cmax decreased 45%, Cmin decreased 50%; half-life: decreased 29%	Possible decreased buprenorphine effects	Green: Administer standard doses	Administer standard doses	Monitor for signs and symptoms of opioid withdrawal; some patients may need an increase in the buprenorphine dose, though study patients did not go into opioid withdrawal
6035	Efavirenz Cetirizine 420	Efavirenz	600 mg x 10 days	No significant change	Cetirizine	10 mg x 1 dose	Cetirizine Cmax decreased 24%		Green: Administer standard doses	Administer standard doses
6051	Efavirenz ATV 436	Efavirenz	600 mg daily 2 hours after atazanavir and ritonavir d 7-20		Atazanavir	400 mg daily d 1-6, then 300 mg daily days 7_-20 with ritonavir 100 mg daily	Atazanavir auc increased 39%, Cmax increased 48%, Cmin increased 14%.	Potential loss of antiviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Use alternative agents
6067	Efavirenz Lumateperone 452	Efavirenz			Lumateperone			Decreased Lumateperon levels	Red: Avoid combination	Do not coadminister: Reduced levels of lumateperon	Avoid combination and use alternative agents
6083	Efavirenz Saquinavir 468	Efavirenz	600 mg daily for 10 days		Saquinavir	1200 mg every 8 hours for 10 days	AUC decreased 62%, Cmin decreased 56%, Cmax decreased %50	Potential loss of antiviral efficacy	Red: Avoid combination	Minimal data to guide interaction, weigh risks and benefits of using this combination	Use alternative agents
6099	Efavirenz Ticagrelor 484	Efavirenz			Ticagrelor			Possible decreased ticagrelor levels	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination and use alternative agents
6115	Efavirenz Warfarin 500	Efavirenz		Not studied	Warfarin		Not studied (may increase or decrease warfarin levels)	Increased or decreased warfarin effects (altered INR, increased risk of bleeding or clotting)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering monitor INR and adjust warfarin as indicated. Monitor for signs and symptons of bleeding.
5988	Efavirenz RFB 373	Efavirenz	600 mg x 14 days	No significant change	Rifabutin	300 mg daily x 14 days	Rifabutin AUC decreased 38%; Cmax decreased 32%; Cmin decreased 45%	Decreased rifabutin effects	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of rifabutin	Increase rifabutin to 450-600 mg daily. May use rifabutin 300 mg three times weekly if not coadministered with a protease inhibitor
6004	Efavirenz Diltiazem 389	Efavirenz	600 mg daily x 14 days	No significant change	Diltiazem	240 mg daily x 21 days	Diltiazem AUC decreased 69%; Cmax decreased 60%; Cmin decreased 63%	Decreased diltiazem effects	Green: Administer standard doses	Administer standard doses	Monitor diltiazem efficacy and to titrate to clinical effect
6020	Efavirenz Atorvastatin 405	Efavirenz	600 mg daily x 15 days	No significant change	Atorvastatin	10 mg daily x 4 days	Atorvastatin AUC decreased 43%, Cmax decreased %14, cmin decreased 69% Atorvastatin and metabolites AUC decreased 32%	Decreased lipid effects	Green: Administer standard doses	Administer standard doses	Monitor for statin efficacy. May need to increase atorvastatin dose
6036	Efavirenz Lorazepam 421	Efavirenz	600 mg x 10 days		Lorazepam	2 mg x 1 dose	Lorazepam AUC no significant change; Cmax increased 16%		Green: Administer standard doses	Administer standard doses
6052	Efavirenz ATV 437	Efavirenz	600 mg daily 2 hours after atazanavir and ritonavir d 7-20		Atazanavir	400 mg daily d 1-6, then 300 mg daily days 7_-20 with ritonavir 100 mg daily	Atazanavir auc increased 39%, Cmax increased 48%, Cmin increased 48%.	Potential loss of antiviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Use alternative agents
6068	Efavirenz G/P 453	Efavirenz			Glecaprevir / Pibrentasvir			decreased pibrenatasvir / glecaprevir effects	Red: Avoid combination	Do not coadminister: Reduced levels of Pibrenatasvir / Glecaprevir	Contraindicated. Use alternative agents.
6084	Efavirenz Saquinavir 469	Efavirenz	600 mg daily for 10 days		Saquinavir	1200 mg every 8 hours for 10 days	AUC decreased 62%, Cmin decreased 56%, Cmax decreased %50	Potential loss of antiviral efficacy	Red: Avoid combination	Minimal data to guide interaction, weigh risks and benefits of using this combination	Use alternative agents
6100	Efavirenz Phenytoin 485	Efavirenz		Not studied (may decrease efavirenz levels)	Phenytoin		Not studied (may decrease phenytoin levels)	Decreased efavirenz and phenytoin effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination and use alternative agents. If coadministering, \monitor phenytoin levels and adjust as indicated	Gabapentin Lamotrigine Tiagabine Topiramate
6116	Efavirenz Warfarin 501	Efavirenz		Not studied	Warfarin		Not studied (may increase or decrease warfarin levels)	Increased or decreased warfarin effects (altered INR, increased risk of bleeding or clotting)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering monitor INR and adjust warfarin as indicated. Monitor for signs and symptons of bleeding.
5989	Efavirenz RFB 374	Efavirenz	600 mg x 14 days	No significant change	Rifabutin	300 mg daily x 14 days	Rifabutin AUC decreased 38%; Cmax decreased 32%; Cmin decreased 45%	Decreased rifabutin effects	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of rifabutin	Increase rifabutin to 450-600 mg daily. May use rifabutin 300 mg three times weekly if not coadministered with a protease inhibitor
6005	Efavirenz Diltiazem 390	Efavirenz	600 mg daily x 15 days	No significant change	Diltiazem	240 mg daily x 21 days	Diltiazem AUC decreased 69%; Cmax decreased 60%; Cmin decreased 63%	Decreased diltiazem effects	Green: Administer standard doses	Administer standard doses	Monitor diltiazem efficacy and to titrate to clinical effect
6021	Efavirenz Atorvastatin 406	Efavirenz	600 mg daily on days 4-18	No significant change	Atorvastatin	10 mg daily on days 0-3 and 15-18	Atorvastatin AUC decreased 43%; Atorvastatin and metabolites AUC decreased 34%	Decreased lipid effects	Green: Administer standard doses	Administer standard doses	Monitor for statin efficacy. May need to increase atorvastatin dose
6037	Efavirenz Lorazepam 422	Efavirenz	600 mg x 10 days		Lorazepam	2 mg x 1 dose	Lorazepam AUC no significant change; Cmax increased 16%		Green: Administer standard doses	Administer standard doses
6053	Efavirenz ATV 438	Efavirenz	600 mg daily days 11-24		Atazanavir	300 mg daily / ritonavir 100 mg daily days 1-10 then 400 mg daily / ritonavir 100 mg daily days 11-24	Atazanavir Cmin decreased 42%, Cmax increased 17%	Potential loss of antiviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Use alternative agents
6069	Efavirenz Pimavanserin 454	Efavirenz			Pimavanserin			Decreased pimavanserin levels	Red: Avoid combination	Do not coadminister: Reduced levels of pimavanserin	Avoid combination and use alternative agents
6085	Efavirenz Artemether / Lumefantrine 470	Efavirenz	600 mg daily x 26 days		Artemether / Lumefantrine	artemether 20mg / lumefantrine 120 mg 4 tablets / dose for 6 doses total in 3 days	Aremether AUC decreased 51%, Cmax decreased 21% Lumefantrine AUC decreased 21%	Potentially compromised antimalarial activity	Orange: Minimal data to guide interaction	Consider using alternative agents	If coadministering,dose adjustment not established. Monitor for anti-malarial efficacy.
6101	Efavirenz Phenytoin 486	Efavirenz		Not studied (may decrease efavirenz levels)	Phenytoin		Not studied (may decrease phenytoin levels)	Decreased efavirenz and phenytoin effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination and use alternative agents. If coadministering, \monitor phenytoin levels and adjust as indicated
6117	Efavirenz NVP 502	Efavirenz	600 mg daily	Efavirenz AUC decreased 22%; Cmin decreased 36%	Nevirapine	200 mg daily x 2 weeks, then 400 mg daily	No significant change	Decreased efavirenz effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Monitor and adjust therapy as indicated; may consider increasing efavirenz to 800 mg daily
5990	Efavirenz RFB 375	Efavirenz	600 mg daily	Not studied	Rifabutin	300 mg or 450 mg twice weekly	On 300 mg rifabutin twice weekly, rifabutin level 2 hours after dose: no significant change; rifabutin level 6 hours post dose: decreased 27%; on 450 mg twice weekly, rifabutin level 2 hours post dose: no significant change; rifabutin level 6 hours post dose: decreased 58%(all values compared to rifabutin alone)	Potential decreased rifabutin effects	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of rifabutin	Increase rifabutin to 450-600 mg daily. May use rifabutin 300 mg three times weekly if not coadministered with a protease inhibitor
6006	Efavirenz Diltiazem 391	Efavirenz	600 mg daily x 28 days	EFV AUC increased 11%, Cmax increased %16, Cmin increased 13%	Diltiazem	240 mg daily x 14 days		Decreased diltiazem effects	Green: Administer standard doses	Administer standard doses	Monitor diltiazem efficacy and to titrate to clinical effect
6022	Efavirenz Atorvastatin 407	Efavirenz	600 mg daily x 15 days	No significant change	Atorvastatin	10 mg daily x 5 days	Atorvastatin AUC decreased 43%; Cmax decreased 14%, Cmin decreased 69%. Atorvastatin and metabolites AUC decreased 32%, Cmin decreased 48%, Cmax decreased 15%	Decreased lipid effects	Green: Administer standard doses	Administer standard doses	Monitor for statin efficacy. May need to increase atorvastatin dose
6038	Efavirenz NFV 423	Efavirenz	600 mg QHS		Nelfinavir	750 mg TID	Nelfinavir clearance: no significant changeM8 clearance: increased 43%		Green: Administer standard doses	Administer standard doses
6054	Efavirenz ATV 439	Efavirenz	600 mg daily days 11-24		Atazanavir	300 mg daily / ritonavir 100 mg daily days 1-10 then 400 mg daily / ritonavir 100 mg daily days 11-24	Atazanavir Cmin decreased 43%, Cmax increased 17%	Potential loss of antiviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Use alternative agents
6070	Efavirenz EE/NGM 455	Efavirenz	600 mg QHS		Ethinyl estradiol / Norgestimate	0.025 mg ethinyl estradiol / 0.25 mg norgestimate	Ethinyl estradiol: no significant change; Norgestromin AUC decreased 64%; Cmax decreased 46%; Cmin decrased 82%	Decreased effects of ethinyl estradiol and norgestimate	Red: Avoid combination	Do not coadminister: Reduced levels of progestin	Use alternative contraceptive method
6086	Efavirenz Artemether / Lumefantrine 471	Efavirenz	600 mg daily x 26 days	EFV AUC decreased 17%	Artemether / Lumefantrine	artemether 20mg / lumefantrine 120 mg 4 tablets / dose for 6 doses total in 3 days	Aremether AUC decreased 51%, Cmax decreased 21% Lumefantrine AUC decreased 21%.	Potentially compromised antimalarial activity	Orange: Minimal data to guide interaction	Consider using alternative agents	If coadministering,dose adjustment not established. Monitor for anti-malarial efficacy.
6102	Efavirenz Phenobarbital 487	Efavirenz		Not studied (may decrease levels)	Phenobarbital		Not studied	Decreased efavirenz effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination and use alternative agents. If coadministering, monitor phenobarbital levels and adjust as indicated	Gabapentin Lamotrigine Tiagabine Topiramate
6118	Efavirenz Midazolam 503	Efavirenz		Not studied	Midazolam		Not studied (may increase midazolam levels)	Increased midazolam effects (eg, increased sedation, confusion, respiratory depression)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Parenteral midazolam can be used with caution when given as a single dose in a monitored situation for procedural sedation. Chronic midazolam administration (oral or intravenous) should be avoided.	Lorazepam
6135	Etravirine RFB 520	Etravirine		Etravirine AUC decreased 37%; Cmax decreased 37%; Cmin decreased 35%	Rifabutin	300 mg daily	Rifabutin AUC decreased 17%; Cmin decreased 24%; 25-O-desacetylrifabutin AUC decreased 17%; Cmax decreased 15%; Cmin decreased 22%	Decreased rifabutin effects	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of rifabutin	Administer rifabutin 300 mg once daily with etravirine. If etravirine and a protease inhibitor are used together, do not coadminister with rifabutin.
6151	Etravirine DTG 536	Etravirine	200 mg BID with darunavir / ritonavir 600 / 100 mg BID		Dolutegravir	50 mg daily	Dolutegravir AUC decreased 25%; Cmin decreased 37%	Potentially reduced dolutegravir effectiveness	Red: Avoid combination	Administer standard doses	Do not coadminister etravirine with dolutegravir unless atazanavir / ritonavir, darunavir / ritonavir, or lopinavir / ritonavir are also part of the regimen. When using this combo and there is known or clinically suspected INSTI resistance, increase dolutegravir dosage to 50 mg BID.
6167	Etravirine EFV 552	Etravirine			Efavirenz				Red: Avoid combination	Do not coadminister: Reduced levels of etravirine	Avoid combination: combining two NNRTIs has not been shown beneficial; use alternate agents
6183	Etravirine Zonisamide 568	Etravirine			Zonisamide			Potiental decreased anticonvulsant effects	Orange: Minimal data to guide interaction	minimal data to guide interaction: weigh risks and benefits of using this combination	if co-administring, monitor for seizure control
6136	Etravirine Posaconazole 521	Etravirine		Not studied (may increase etravirine levels)	Posaconazole		Not studied		Green: Administer standard doses	Administer standard doses	Monitor for etravirine related toxicities
6152	Etravirine DTG 537	Etravirine	200 mg BID with lopinavir / ritonavir 400 / 100 mg BID		Dolutegravir	50 mg daily	Dolutegravir AUC increased 11%; Cmin increased 28%		Red: Avoid combination	Administer standard doses	Do not coadminister etravirine with dolutegravir unless atazanavir / ritonavir, darunavir / ritonavir, or lopinavir / ritonavir are also part of the regimen. When using this combo and there is known or clinically suspected INSTI resistance, increase dolutegravir dosage to 50 mg BID.
6168	Etravirine NVP 553	Etravirine			Nevirapine				Red: Avoid combination	Do not coadminister: Reduced levels of etravirine	Avoid combination: :combining two NNRTIs has not been shown beneficial use alternate agents
6184	Etravirine Sertraline 569	Etravirine			Sertraline			Potiential decreaed Sertaline effects	Orange: Minimal data to guide interaction	minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministring, monitor for theraptutic effectiveness of Sertaline
6137	Etravirine Fluconazole 522	Etravirine	200 mg BID	Etravirine AUC increased 86%; Cmax increased 75%; Cmin increased 109%	Fluconazole	200 mg QAM	No significant change	Increased etravirine effects	Green: Administer standard doses	Administer standard doses	Monitor for fluconazole associated toxicities
6153	Etravirine Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir 538	Etravirine		Not studied	Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir		Not studied (may decrease paritaprevir levels)	Potential decrease in anti-HCV efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of anti-HCV agents	Use alternative agents
6169	Etravirine Phenobarbital 554	Etravirine			Phenobarbital			Potential decreased etravirine effects; potential decreased anticonvulsants effects	Red: Avoid combination	Do not coadminister: Potential for reduced levels of etravirine and phenobarbital	Avoid combination and use alternative agents
6185	Etravirine Trazodone 570	Etravirine			Trazodone			Potiential decreaed Trazodone effects	Orange: Minimal data to guide interaction	minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministring, monitor for theraptutic effectiveness of Trazodone
6138	Etravirine Sildenafil 523	Etravirine			Sildenafil	50 mg x 1	Sildenafil AUC decreased 57%; Cmax decreased 45%	Decreased sildenafil effects	Green: Administer standard doses	Administer standard doses	Monitor for sildenafil efficacy and titrate to effect
6154	Etravirine ATV/c 539	Etravirine		Not studied	Atazanavir / Cobicistat		Not studied; Potential decreased atazanavir and cobicistat levels)	Potential loss of antiviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Use alternative agents
6170	Etravirine CBZ 555	Etravirine			Carbamazepine			Potential decreased etravirine effects; potential decreased anticonvulsants effects	Red: Avoid combination	Do not coadminister: Potential for reduced levels of etravirine and carbamazepine
6186	Etravirine Warfarin 571	Etravirine			Warfarin			Potential for increased Warfarin concentration	Orange: Minimal data to guide interaction	minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministring, monitor INR
6139	Etravirine Midazolam 524	Etravirine			Midazolam		Midozolam AUC decreased 31%; active metabolite Cmax increased 57%	decreased levels of midazolam	Green: Administer standard doses	Administer standard doses	Monitor for theraputive effectiveness of midazolam
6155	Etravirine Bedaquiline 540	Etravirine			Bedaquiline			potentially reduced levels of bedaquiline	Red: Avoid combination	Do not coadminister: Potential for reduced levels of bedaquiline
6171	Etravirine Phenytoin 556	Etravirine			Phenytoin			Potential decreased etravirine effects; potential decreased anticonvulsants effects	Red: Avoid combination	Do not coadminister: Potential for reduced levels of etravirine and phenytoin
6187	Etravirine Diltiazem 572	Etravirine			Diltiazem			Potential decreased dilitazem efficacy	Orange: Minimal data to guide interaction	minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministring, titrate dilitazem based on clinical response
6140	Etravirine Linagliptin 525	Etravirine			Linagliptin			Possible decrease in antihyperglycemic effects	Green: Administer standard doses	Administer standard doses	Monitor glycemic control
6156	Etravirine DTG 541	Etravirine	200 mg BID		Dolutegravir	50 mg daily	Dolutegravir AUC decreased 71%; Cmin decreased 88%	Potentially reduced dolutegravir effectiveness	Red: Avoid combination	Do not coadminister: Potential for reduced levels of dolutegravir	Do not coadminister etravirine with dolutegravir unless atazanavir / ritonavir, darunavir / ritonavir, or lopinavir / ritonavir are also part of the regimen. If one of these boosted PIs is present and known or clinically suspected INSTI resistance, increase dolutegravir dosage to 50 mg BID.
6172	Etravirine Tamsulosin 557	Etravirine			Tamsulosin			Decreased tamsulosin effects	Orange: Minimal data to guide interaction	Adjust dosing to avoid decreased levels of tamsulosin	If coadministring, monitor for theraptutic effectiveness of tamsulosin after 2-4 weeks. Increase dose to 0.8mg daily for patients who fail to respond to 0.4 mg dose.
6188	Etravirine Verapamil 573	Etravirine			Verapamil			Potential decreased verampil efficacy	Orange: Minimal data to guide interaction	minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministring, titrate verapamil based on clinical response
6141	Etravirine Saxagliptin 526	Etravirine			Saxagliptin			Possible decrease in antihyperglycemic effects	Green: Administer standard doses	Administer standard doses	Monitor glycemic control
6157	Etravirine EBR/GZR 542	Etravirine		Not studied	Elbasvir / Grazoprevir		Not studied (may decrease grazprevir levels)	Potentially decreased elbasvir, grazoprevir levels expected	Red: Avoid combination	Do not coadminister: Potential for reduced levels of elbasvir / grazoprevir	Avoid combination. Use alternative agents
6173	Etravirine Clopidogrel 558	Etravirine			Clopidogrel			Potential decreased clopidogrel effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination and use alternative agents
6189	Etravirine ATV 574	Etravirine		Etravirine AUC increased 30%; Cmax increased 30%; Cmin decreased 26%	Atazanavir	300 mg daily with 100 mg ritonavir daily	Atazanavir AUC decreased 14%; Cmin decreased 38%	Potential for increased etravirine effects			When using atazanavir 300 mg plus ritonavir 100 mg once daily use etravirine standard dose.
6142	Etravirine Voriconazole 527	Etravirine	200 mg BID	Etravirine AUC increased 36%; Cmin increased 52%; Cmax increased 26%	Voriconazole	200 mg BID	Voriconazole Cmin increased 23%	Potential for increased etravirine effects	Green: Administer standard doses	Administer standard doses
6158	Etravirine St. John's Wort (Hypericum perforatum) 543	Etravirine		Not studied	St. John's Wort		Not studied	loss of virologic response	Red: Avoid combination	Do not coadminister: Potential for reduced levels of ETR	Contraindicated. Use alternative agents.
6174	Etravirine Elvitegravir / Cobicistat / Emtricitabine / Tenofovir alafenamide 559	Etravirine	200 mg BID with ritonavir 100 mg daily	No significant change	Elvitegravir / Cobicistat / Emtricitabine / Tenofovir alafenamide	Elvitegravir 150 mg daily	No significant change	Potentially decreased or increased elvitegravir, cobicistat and / or etravirine effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination and use alternative agents
6143	Etravirine DRV 528	Etravirine	100 mg BID	Etravirine AUC decreased 37%; Cmax decreased 32%; Cmin decreased 49%	Darunavir	600 mg BID with 100 mg ritonavir BID	No significant change		Green: Administer standard doses	Administer standard doses
6159	Etravirine RPT 544	Etravirine			Rifapentine			Potential decreased etravirine effects	Red: Avoid combination	Do not coadminister: Potential for reduced levels of etraviorine
6175	Etravirine Bosentan 560	Etravirine			Bosentan			Potential decreased etravirine effects; potential decreased bosentran effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	If coadministring, monitor bosentran efficacy and virologic response
6128	Etravirine RTV 513	Etravirine			Ritonavir	600 mg BID		Significant decrease in etravirine concentration and loss of theraputic effect	Yellow: Adjust dosing	Adjust dosing to avoid decreased levels of etravirine
6144	Etravirine DRV 529	Etravirine	200 mg BID	Etravirine AUC increased 80%; Cmax increased 81%; Cmin increased 67% (compared to etravirine 100 mg BID)	Darunavir		Darunavir AUC increased 15%		Green: Administer standard doses	Administer standard doses
6160	Etravirine RIF 545	Etravirine			Rifampin			Significant decrease in etravirine efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of etravirine
6176	Etravirine Clarithromycin 561	Etravirine		Etravirine AUC increased 42%; Cmax increased 46%; Cmin increased 46%	Clarithromycin	500 mg BID	Clarithromycin AUC decreased 37%; Cmax decreased 34%; Cmin decreased 53%; 14-hydroxyclarithromycin AUC increased 21%; Cmax increased 33%	Increased etravirine effects; decreased clarithromycin effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Use alternative macrolide (consider use of azithromycin) for MAC	Azithromycin
6129	Etravirine Atorvastatin 514	Etravirine		No significant change	Atorvastatin	40 mg daily	Atorvastatin AUC decreased 37% 2-hydroxyatorvastatin AUC increased 27%; Cmax increased 76%	Decreased atorvastatin effects	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of atorvastatin	Consider low dose atorvastatin and titrate to effect; monitor for myopathy
6145	Etravirine Ethinyl estradiol / Norethindrone acetate 530	Etravirine			Ethinyl estradiol / Norethindrone acetate	0.035 mg EE / 1 mg NE daily	Ethinyl estradiol AUC increased 22%; Cmax increased 33%; Norethindrone Cmin decreased 22%		Green: Administer standard doses	Administer standard doses
6161	Etravirine G/P 546	Etravirine			Glecaprevir / Pibrentasvir		Not studied (may decrease grazprevir levels)	Potentially decreased glecaprevir / pibrentasvir levels expected	Red: Avoid combination	Do not coadminister: Potential for reduced levels of glecaprevir / Pibrentasvir	Avoid combination. Use alternative agents
6177	Etravirine Artemether / Lumefantrine 562	Etravirine	200 mg BID	No significant change	Artemether / Lumefantrine	artemether / lumefantrine 80 / 480 mg	Artemether AUC decreased 38%; Lumefantrine AUC decreased 13%	Decreased antimalarial effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Use with caution; avoid if possible
6130	Etravirine Daclatasvir 515	Etravirine	600 mg daily	Not studied	Daclatasvir	120 mg daily	AUC increased 37% and Cmin decreased 17%.	Potential loss of anti-HCV efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of daclatasvir	Increase daclatasvir dose to 90 mg daily.
6146	Etravirine Paroxetine 531	Etravirine	125 mg BID	No significant change	Paroxetine	20 mg daily	No significant change		Green: Administer standard doses	Administer standard doses
6162	Etravirine Lumateperone 547	Etravirine			Lumateperone			Decreased Lumateperon levels	Red: Avoid combination	Do not coadminister: Reduced levels of lumateperon	Avoid combination and use alternative agents
6178	Etravirine Itraconazole 563	Etravirine		Not studied (may increase etravirine levels)	Itraconazole		Not studied (may decrease itraconazole levels)	Decreased itraconazole effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, dose adjustment not established. Monitor itraconazole levels and etravirine toxicity.
6131	Etravirine MVC 516	Etravirine	200 mg BID		Maraviroc	300 mg BID	Maraviroc AUC decreased 53%; Cmax decreased 60%; Cmin decreased 39%	Decreased maraviroc effects	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of maraviroc	Increase maraviroc to 600 mg BID when combined with etravirine. When etravirine and maraviroc are coadministered with a strong CYP3A4 inhibitor, decrease maraviroc dose to 150 mg BID
6147	Etravirine RAL 532	Etravirine	200 mg BID	Etravirine Cmin increased 17%	Raltegravir	400 mg BID	Raltegravir Cmin decreased 34%		Green: Administer standard doses	Administer standard doses
6163	Etravirine Cariprazine 548	Etravirine			Cariprazine			Potential decreased cariprazine effects	Red: Avoid combination	Do not coadminister: potientially reduced levels of cariprazine	Contraindicated. Use alternative agents.
6179	Etravirine Lumefantrine 564	Etravirine	200 mg BID	No significant change	Lumefantrine	artemether / Lumefantrine 80 / 480 mg	Lumefantrine AUC decreased 13%	Decreased antimalarial effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, monitor for anti-malarial efficacy.
6132	Etravirine MVC 517	Etravirine	200 mg BID with darunavir / ritonavir 600 / 100 mg BID	No significant change on etravirine, darunavir or ritonavir pharmacokinetics	Maraviroc	300 mg BID	Maraviroc AUC increased 210%; Cmax increased 77%; Cmin increased 430%	Increased maraviroc effects	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of maraviroc	Increase maraviroc to 600 mg BID when combined with etravirine. When etravirine and maraviroc are coadministered with a strong CYP3A4 inhibitor, decrease maraviroc dose to 150 mg BID
6148	Etravirine Methadone 533	Etravirine			Methadone	60-130 mg daily	R-methadone: no significant effect; S-methadone: no significant effect		Green: Administer standard doses	Administer standard doses
6164	Etravirine Pimavanserin 549	Etravirine			Pimavanserin			Potential decreased pimavanserin effects	Red: Avoid combination	Do not coadminister: potientially reduced levels of pimavanserin	Contraindicated. Use alternative agents.
6180	Etravirine Ethosuximide 565	Etravirine			Ethosuximide			Potiental decreased anticonvulsant effects	Orange: Minimal data to guide interaction	minimal data to guide interaction: weigh risks and benefits of using this combination	if co-administring, monitor for seizure control
6133	Etravirine MVC 518	Etravirine	200 mg BID with darunavir / ritonavir 600 / 100 mg BID		Maraviroc	150 mg BID	Maraviroc AUC increased 3.10 fold; Cmax increased 1.76 fold; Cmin increased 5.27 fold	Increased maraviroc effects	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of maraviroc	Increase maraviroc to 600 mg BID when combined with etravirine. When etravirine and maraviroc are coadministered with a strong CYP3A4 inhibitor, decrease maraviroc dose to 150 mg BID
6149	Etravirine Ranitidine 534	Etravirine	100 mg x 1	No significant change	Ranitidine	150 mg BID x 11 days			Green: Administer standard doses	Administer standard doses
6165	Etravirine SOF/VEL 550	Etravirine		Not studied	Sofosbuvir / Velpatasvir		Not studied (may decrease velpatasvir and sofosbuvir levels)	Potential loss of anti-HCV efficacy	Red: Avoid combination	Do not coadminister: potientially reduced levels of velpatasvir	Contraindicated. Use alternative agents.
6181	Etravirine Lacosamide 566	Etravirine			Lacosamide			Potiental decreased anticonvulsant effects	Orange: Minimal data to guide interaction	minimal data to guide interaction: weigh risks and benefits of using this combination	if co-administring, monitor for seizure control
6134	Etravirine MVC 519	Etravirine	200 mg BID	No significant change	Maraviroc	300 mg BID	Maraviroc AUC decreased 53%; Cmax decreased 60%; Cmin decreased 39%		Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of maraviroc	Increase maraviroc to 600 mg BID when combined with etravirine. When etravirine and maraviroc are coadministered with a strong CYP3A4 inhibitor, decrease maraviroc dose to 150 mg BID
6150	Etravirine Omeprazole 535	Etravirine	100 mg x 1	Etravirine AUC increased 41%	Omeprazole	40 mg daily x 11 days			Green: Administer standard doses	Administer standard doses
6166	Etravirine SOF/VEL 551	Etravirine		Not studied	Sofosbuvir / Velpatasvir / Voxilaprevir		Not studied (may decrease velpatasvir and voxilaprevirlevels)	Potential loss of anti-HCV efficacy	Red: Avoid combination	Do not coadminister: potientially reduced levels of velpatasvir and voxilaprevir	Contraindicated. Use alternative agents.
6182	Etravirine Tiagabine 567	Etravirine			Tiagabine			Potiental decreased anticonvulsant effects	Orange: Minimal data to guide interaction	minimal data to guide interaction: weigh risks and benefits of using this combination	if co-administring, monitor for seizure control
6199	Nevirapine Isavuconazole 584	Nevirapine			Isavuconazole			Possible decreased Isavuconazole levels	Green: Administer standard doses	Administer standard doses	monitor for isravucanazole concentrations and anti fungal response
6215	Nevirapine Medroxyprogesterone acetate 600	Nevirapine			Medroxyprogesterone acetate	150 mg	Progesterone levels): no significant change		Green: Administer standard doses	Administer standard doses
6231	Nevirapine Ethinyl estradiol / Norethindrone acetate 616	Nevirapine			Ethinyl estradiol / Norethindrone acetate	Ethinyl estradiol 0.035 mg / Norethindrone 1 mg daily x 30 days	Ethinyl estradiol: AUC decreased 23%; half-life: decreased 44%; Norethindrone: AUC decreased 18%; half-life: decreased 15%	Possible contraceptive failure	Red: Avoid combination	Do not coadminister: Reduced levels of ethinyl estradiol and progesterone	Use alternative contraceptive method
6247	Nevirapine Ticagrelor 632	Nevirapine			Ticagrelor			Possible decreased ticagrelor levels	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination and use alternative agents
6200	Nevirapine Fluconazole 585	Nevirapine	200 mg daily		Fluconazole	200 mg daily x 40 days	No significant change	Increased nevirapine effects	Green: Administer standard doses	Administer standard doses	Monitor for nevirapine toxicity
6216	Nevirapine Daclatasvir 601	Nevirapine		Cmin decreased 16%	Daclatasvir		Rifabutin AUC increased 17%, metabolite AUC increased 24%		Green: Administer standard doses	Administer standard doses
6232	Nevirapine ETR 617	Nevirapine	200 mg daily x 2 weeks then 200 mg BID x 2 weeks	levels): increased 15-30%	Etravirine		Etravirine AUC decreased 55%	Decreased etravirine and nevirapine effects	Red: Avoid combination	Do not coadminister: Reduced levels of etravirine	Use alternative agents
6248	Nevirapine Bosentan 633	Nevirapine			Bosentan			Potential decreased etravirine effects; potential decreased bosentran effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	If coadministring, monitor bosentran efficacy and virologic response
6201	Nevirapine Fluconazole 586	Nevirapine	200 mg daily		Fluconazole	200 mg three times weekly		Potential for increased nevirapine effects	Green: Administer standard doses	Administer standard doses	Monitor for nevirapine toxicity
6217	Nevirapine AZT, ZDV 602	Nevirapine	200 mg daily x 14 days; 200 mg BID x 14 days	No significant change	Zidovudine	100-200 mg TID			Green: Administer standard doses	Administer standard doses
6233	Nevirapine Ketoconazole 618	Nevirapine	200 mg daily x 14 days; 200 mg BID x 14 days		Ketoconazole	400 mg daily	Ketoconazole AUC decreased 72%; Cmax decreased 44%	Decreased ketoconazole effects	Red: Avoid combination	Do not coadminister: Reduced levels of ketoconazole	Use alternative agents
6249	Nevirapine Warfarin 634	Nevirapine			Warfarin			Potential decreased warfarin effects (eg, altered INR, increased risk of clotting)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering monitor INR and adjust warfarin as indicated. Monitor for signs and symptons of bleeding.
6202	Nevirapine Bupropion 587	Nevirapine			Bupropion			Decreased bupropion effects	Green: Administer standard doses	Administer standard doses	Monitor for signs and symptoms of depression and titrate bupropion to effect
6218	Nevirapine Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir 603	Nevirapine			Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir		Not studied (may decrease paritaprevir levels)	Potential decrease in anti-HCV efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of anti-HCV agents	Use alternative agents
6234	Nevirapine LNG 619	Nevirapine			Levonorgestrel		Levonorgestrel AUC increased 35%		Red: Avoid combination	Do not coadminister: Reduced levels of levonorgestrel
6250	Nevirapine Caffeine / Ergotamine 635	Nevirapine	200 mg daily x 2 weeks then 200 mg BID x 28 days	No significant change	Caffeine / Ergotamine		Not studied (may decrease ergot levels)	Ergotamine levels may be decreased	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, monitor for ergot efficacy
6203	Nevirapine Escitalopram 588	Nevirapine			Escitalopram			Decreased escitalopram effects	Green: Administer standard doses	Administer standard doses	Monitor for signs and symptoms of depression and titrate escitalopram to effect
6219	Nevirapine Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir 604	Nevirapine	200 mg BID	Nevirapine AUC decreased 27% (at week 4); Nevirapine AUC no significant change (at week 10)Nevirapine AUC with rifampicin approximates nevirapine baseline without rifampicin at week 10.	Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir		Not studied (may decrease paritaprevir levels)	Potential decrease in HCV agent efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of dasabuvir, ombitasvir, and paritaprevir	Use alternative agents
6235	Nevirapine Lumateperone 620	Nevirapine			Lumateperone			Decreased Lumateperon levels	Red: Avoid combination	Do not coadminister: Reduced levels of lumateperon	Avoid combination and use alternative agents
6251	Nevirapine CBZ 636	Nevirapine			Carbamazepine			Potential decreased anticonvulsant and NVP concentration	Orange: Minimal data to guide interaction	minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministring, monitor anticonvulsant and NVP concentration
6204	Nevirapine Sertraline 589	Nevirapine			Sertraline			Decreased sertaline effects	Green: Administer standard doses	Administer standard doses	Monitor for signs and symptoms of depression and titrate sertaline to effect
6220	Nevirapine EBR/GZR 605	Nevirapine			Elbasvir / Grazoprevir		Not studied (may decrease grazprevir levels)	Potentially decreased elbasvir, grazoprevir levels expected	Red: Avoid combination	Do not coadminister: Potential for reduced levels of elbasvir / grazoprevir	Avoid combination. Use alternative agents
6236	Nevirapine RPT 621	Nevirapine			Rifapentine		Cmin decreased 27%	Decreased nevirapine effects	Red: Avoid combination	Do not coadminister: Reduced levels of nevirapine	Contraindicated. Use alternative agents.
6252	Nevirapine Diltiazem 637	Nevirapine			Diltiazem			Potential decreased dilitazem efficacy	Orange: Minimal data to guide interaction	minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministring, titrate dilitazem based on clinical response
6205	Nevirapine Trazodone 590	Nevirapine			Trazodone			Decreased trazadone effects	Green: Administer standard doses	Administer standard doses	Monitor for signs and symptoms of depression and titrate trazadone to effect
6221	Nevirapine EBR/GZR 606	Nevirapine	200 mg BID	Nevirapine AUC decreased 31%; Cmax decreased 36%; Cmin decreased 21%	Elbasvir / Grazoprevir		Not studied (may decrease grazprevir levels)	Decreased elbasvir, grazoprevir levels expected	Red: Avoid combination	Do not coadminister: Potential for reduced levels of elbasvir / grazoprevir	Contraindicated. Use alternative agents.
6237	Nevirapine RIF 622	Nevirapine	200 mg daily x 14 days; 200 mg BID x 14 days		Rifampin	600 mg daily	No significant change	Decreased nevirapine effects	Red: Avoid combination	Do not coadminister: Reduced levels of nevirapine	Use alternative agents	Rifabutin
6253	Nevirapine SQV 638	Nevirapine	200 mg daily x 14 days	Not studied	Saquinavir	600 mg (hard gel caps) TID	Saquinavir AUC decreased 24%; Cmax decreased 28%	Decreased saquinavir effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Use alternative agents
6190	Nevirapine Daclatasvir 575	Nevirapine			Daclatasvir	120 mg daily	AUC increased 37% and Cmin decreased 17%.	Potential loss of anti-HCV efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of daclatasvir	Increase daclatasvir dose to 90 mg daily.
6206	Nevirapine Atorvastatin 591	Nevirapine			Atorvastatin		Atorvastatin AUC decreased 32%-43%	Decreased lipid effects	Green: Administer standard doses	Administer standard doses	Monitor for statin efficacy. May need to increase atorvastatin dose
6222	Nevirapine Elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide 607	Nevirapine	200 mg daily x 2 weeks, 200 mg BID x 28 days	Not studied	Elvitegravir / Cobicistat / Emtricitabine / Tenofovir alafenamide		Not studied	Potentially decreased or increased elvitegravir, cobicistat and / or nevirapine effects	Red: Avoid combination	Do not coadminister: Potential for reduced levels of elvitegravir / cobicistat	Use alternative agents
6238	Nevirapine RIF 623	Nevirapine	200 mg daily x 14 days; 200 mg BID x 14 days		Rifampin		Not studied	Decreased nevirapine effects	Red: Avoid combination	Do not coadminister: Reduced levels of nevirapine	Use alternative agents	Rifabutin
6254	Nevirapine DRV 639	Nevirapine		AUC increased 110%	Darunavir			Increased Nevirapine effects, increased risk of hepatotoxcity	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Use alternative agents
6191	Nevirapine Daclatasvir 576	Nevirapine	200 mg daily x 14 days; 200 mg	Nevirapine Cmin decreased 16%	Daclatasvir		Not studied (may decrease daclatasvir levels)	Potential loss of anti-HCV efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of daclatasvir	Increase daclatasvir dose to 90 mg daily.
6207	Nevirapine Linagliptin 592	Nevirapine			Linagliptin			Possible decrease in antihyperglycemic effects	Green: Administer standard doses	Administer standard doses	Monitor glycemic control
6223	Nevirapine St. John's Wort (Hypericum perforatum) 608	Nevirapine			St. John's Wort		Not studied	loss of virologic response	Red: Avoid combination	Do not coadminister: Potential for reduced levels of NVP	Contraindicated. Use alternative agents
6239	Nevirapine RIF 624	Nevirapine	200 mg daily x 14 days; 200 mg BID x 14 days		Rifampin	450 mg if < 55 kg and 600 mg if > 55 kg x 7 days		Decreased nevirapine effects	Red: Avoid combination	Do not coadminister: Reduced levels of nevirapine	Use alternative agents	Rifabutin
6255	Nevirapine MMF, MPA 640	Nevirapine	200 mg BID x 43 doses	No significant change	Mycophenolate	500 mg BID x 8 weeks	Not studied		Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Use alternative agents
6192	Nevirapine FPV 577	Nevirapine	200 mg BID	Nevirapine AUC decreased 46%; Cmax decreased 42%	Fosamprenavir	1400 mg BID	Fosamprenavir AUC decreased 33%; Cmax decreased 25%; Cmin decreased 35%	Decreased fosamprenavir effects	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of fosamprenavir	Do not use with fosamprenavir alone. Ritonavir boosted fosamprenavir (700 / 100 mg BID) can be considered	Consider ritonavir-boosted fosamprenavir
6208	Nevirapine RTV 593	Nevirapine	200 mg daily x 14 days; 200 mg BID x 14 days	Nevirapine AUC decreased 40%	Ritonavir	600 mg BID	No significant change		Green: Administer standard doses	Administer standard doses	No dose adjustment necessary
6224	Nevirapine SOF/VEL 609	Nevirapine	200 mg x 1	Nevirapine AUC decreased 79%; Cmax decreased 20%; Cmin decreased 60%; half-life: decreased 66%	Sofosbuvir / Velpatasvir		Potential decrease in sofosbuvir and velpatasvir levels).	Potential loss of anti-HCV efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of sofosbuvir	Use alternative agents
6240	Nevirapine RIF 625	Nevirapine	200 mg daily x 14 days; 200 mg BID x 14 days		Rifampin	600 mg daily		Decreased nevirapine effects	Red: Avoid combination	Do not coadminister: Reduced levels of nevirapine	Use alternative agents	Rifabutin
6256	Nevirapine Clarithromycin 641	Nevirapine	200 mg daily x 14 days; 200 mg BID x 14 days		Clarithromycin	500 mg BID	Clarithromycin AUC decreased 31%; Cmax decreased 23%; Cmin decreased 56%; 14-hydroxy clarithromycin AUC increased 42%, Cmax increased 47%	Decreased clarithromycin effects but increased metabolite concentrations	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits when using this combination	Consider using alternative agents such as Azithromycin
6193	Nevirapine FPV 578	Nevirapine	200 mg BID	Not studied	Fosamprenavir	700 mg fosamprenavir BID with 100 mg ritonavir BID	No significant change		Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of fosamprenavir	Do not use with fosamprenavir alone. Ritonavir boosted fosamprenavir (700 / 100 mg BID) can be considered
6209	Nevirapine MVC 594	Nevirapine	200 mg BID	Nevirapine AUC no significant change	Maraviroc	300 mg single dose	Maraviroc Cmax increased 54%		Green: Administer standard doses	Administer standard doses	Use standard dose maraviroc. If coadministering with nevirapine plus a protease inhibitor, reduce dose of maraviroc to 150 mg BID
6225	Nevirapine Artemether / Lumefantrine 610	Nevirapine			Artemether / Lumefantrine	artemether / lumefantrine 80 / 480 mg	Artemether AUC decreased 72%; Cmax decreased 61%; Lumefantrine AUC decreased 21%; Cmax decreased 30%	Potentially increased treatment failure	Red: Avoid combination	Do not coadminister: Reduced levels of arthemether / lumifantrine	Use alternative agents
6241	Nevirapine Pimavanserin 626	Nevirapine			Pimavanserin			Decreased pimavanserin levels	Red: Avoid combination	Do not coadminister: Reduced levels of pimavanserin	Avoid combination and use alternative agents
6257	Nevirapine CsA 642	Nevirapine			Cyclosporine			decreased effects of immunosuppresant	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits when using this combination	if co administiring, monitor immunosuppressant efficacy
6194	Nevirapine IDV 579	Nevirapine	200 mg daily x 14 days; 200 mg BID x 14 days		Indinavir	800 mg Q8H	Indinavir AUC decreased 31%; Cmax decreased 15%, Cmin decreased 44%	Decreased indinavir effects	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of indinavir	Increase indinavir to 1000 mg Q8H
6210	Nevirapine RFB 595	Nevirapine	200 mg daily x 14 days; 200 mg BID x 14 days	No significant change in nevirapine Cmin	Rifabutin	150 or 300 mg daily	AUC increased 17%, Cmax increased 28% and 25-O-desacetyl-rifabutin AUC increased 24%	Decreased antiviral efficacy	Green: Administer standard doses	Administer standard doses
6226	Nevirapine Artemether / Lumefantrine 611	Nevirapine			Artemether / Lumefantrine	artemether / lumefantrine 80 / 480 mg	Lumefantrine AUC decreased 21%; Cmax decreased 30%	Potentially increased treatment failure	Red: Avoid combination	Do not coadminister: Reduced levels of arthemether / lumifantrine	Use alternative agents
6242	Nevirapine Cariprazine 627	Nevirapine			Cariprazine			Potential decreased cariprazine effects	Red: Avoid combination	Do not coadminister: potientially reduced levels of cariprazine	Contraindicated. Use alternative agents.
6258	Nevirapine TDF 643	Nevirapine	200-400 mg daily	Not studied	Tenofovir Disoproxil Fumarate			Potential early virologic failure			Use caution when coadministering tenofovir, didanosine and either efavirenz or nevirapine in treatment naive patients
6195	Nevirapine Methadone 580	Nevirapine	200 mg daily x 14 days; 200 mg BID ³7 days	Nevirapine AUC decreased 46%; Cmax decreased 42%	Methadone	stable dose	Not reported	Decreased methadone effects	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of methadone	If coadministering monitor for signs and symptoms of methadone withdrawal. Some patients may require an increased methadone dose
6211	Nevirapine RFB 596	Nevirapine	200 mg daily x 14 days; 200 mg BID x 14 days	AUC decreased 31%	Rifabutin		AUC increased 26%	Decreased antiviral efficacy	Green: Administer standard doses	Administer standard doses
6227	Nevirapine Artemether / Lumefantrine 612	Nevirapine			Artemether / Lumefantrine	artemether / lumefantrine 80 mg / 480 mg x 6 doses	Lumefantrine AUC increased 56%; Cmax increased 24%; half-life: no significant change; clearance: decreased 36%		Red: Avoid combination	Do not coadminister: Reduced levels of arthemether / lumifantrine	Use alternative agents
6243	Nevirapine SOF/VEL 628	Nevirapine			Sofosbuvir / Velpatasvir		Not studied (may decrease velpatasvir levels)	Potential loss of anti-HCV efficacy	Red: Avoid combination	Do not coadminister: potientially reduced levels of velpatasvir	Contraindicated. Use alternative agents.
6196	Nevirapine Methadone 581	Nevirapine	200 mg daily x 14 days; 200 mg BID ³7 days	Nevirapine AUC increased 25%; Cmax increased 17%; Cmin increased 32%	Methadone	Stable methadone dose	Methadone AUC decreased 51%; Cmax decreased 36%	Decreased methadone effects (eg, methadone withdrawal)	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of methadone	If coadministering monitor for signs and symptoms of methadone withdrawal. Some patients may require an increased methadone dose
6212	Nevirapine DRV 597	Nevirapine	200 mg BID	Nevirapine AUC increased 110%; Cmax increased 115%; Cmin increased 135%; half-live: decreased 52% (data compared to historical controls)	Darunavir	400 mg BID with ritonavir 100 mg BID	Darunavir AUC increased 24%; Cmax increased 40%	Potential for increased darunavir effects; Potential for increased nevirapine effects	Green: Administer standard doses	Administer standard doses
6228	Nevirapine ATV 613	Nevirapine	200 mg BID days 1-23	No significant change	Atazanavir	300 mg atazanavir daily with 100 mg ritonavir daily	Atazanavir AUC decreased 42%; Cmax decreased 28%; Cmin decreased 72%	Decreased atazanavir effects	Red: Avoid combination	Do not coadminister: Reduced levels of atazanavir	Use alternative agents
6244	Nevirapine SOF/VEL 629	Nevirapine			Sofosbuvir / Velpatasvir / Voxilaprevir		Not studied (may decrease velpatasvir and voxilaprevirlevels)	Potential loss of anti-HCV efficacy	Red: Avoid combination	Do not coadminister: potientially reduced levels of velpatasvir and voxilaprevir	Contraindicated. Use alternative agents.
6197	Nevirapine Methadone 582	Nevirapine	200 mg daily x 14 days; 200 mg BID ³7 days	Nevirapine AUC increased 26%; Cmax increased 21%; Cmin increased 35%	Methadone	Stable methadone maintenance	Methadone AUC decreased 46%	Decreased methadone effects (eg, methadone withdrawal; interaction observed one week into therapy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of methadone	If coadministering monitor for signs and symptoms of methadone withdrawal. Some patients may require an increased methadone dose
6213	Nevirapine DTG 598	Nevirapine	200 mg BID	Nevirapine Cmin increased 22%	Dolutegravir	50 mg daily	Dolutegravir AUC decreased 19%; Cmin decreased 34%		Green: Administer standard doses	Administer standard doses
6229	Nevirapine ATV 614	Nevirapine	200 mg BID days 1-23	Not studied	Atazanavir	400 mg atazanavir daily with 100 mg ritonavir daily	Atazanavir AUC decreased 19%; Cmax no significant change; Cmin decreased 59%	Decreased atazanavir effects	Red: Avoid combination	Do not coadminister: Reduced levels of atazanavir	Use alternative agents
6245	Nevirapine Tamsulosin 630	Nevirapine			Tamsulosin			Decreased tamsulosin effects	Orange: Minimal data to guide interaction	Adjust dosing to avoid decreased levels of tamsulosin	If coadministring, monitor for theraptutic effectiveness of tamsulosin after 2-4 weeks. Increase dose to 0.8mg daily for patients who fail to respond to 0.4 mg dose.
6198	Nevirapine Methadone 583	Nevirapine	200 mg daily x 14 days; 200 mg BID ³7 days		Methadone	stable dose: racemic methadone 35-220 mg daily; (R)-methadone 45-115 mg daily	racemic methadone AUC decreased 37%; (R)-methadone AUC decreased 44%	Decreased methadone effects (eg, withdrawal)	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of methadone	If coadministering monitor for signs and symptoms of methadone withdrawal. Some patients may require an increased methadone dose
6214	Nevirapine Paclitaxel 599	Nevirapine	200 mg daily x 2 weeks then 200 mg BID x 28 days	No significant change	Paclitaxel	100 mg / square meter infusion over 3 hours	Not studied		Green: Administer standard doses	Administer standard doses
6230	Nevirapine Ethinyl estradiol / Norethindrone acetate 615	Nevirapine			Ethinyl estradiol / Norethindrone acetate	Ethinyl estradiol 0.035 mg / Norethindrone 1 mg x 1 dose	Ethinyl estradiol AUC decreased 19%; Cmax no significant change. Norethindrone AUC decreased 18%	Possible contraceptive failure	Red: Avoid combination	Do not coadminister: Reduced levels of ethinyl estradiol and progesterone	Use alternative contraceptive method	Barrier devices; Condoms
6246	Nevirapine Itraconazole 631	Nevirapine			Itraconazole		Itraconazole AUC decreased 61%	Decreased itraconazole effects and possible NVP concentrati	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination and use alternative agents
6263	Rilpivirine Atorvastatin 648	Rilpivirine	150 mg daily	No significant change	Atorvastatin	40 mg daily	Atorvastatin Cmin decreased 15%; Cmax increased 35%		Green: Administer standard doses	Administer standard doses
6279	Rilpivirine RIF 664	Rilpivirine	150 mg daily	Rilpivirine AUC decreased 80%; Cmin decreased 89%; Cmax decreased 69%	Rifampin	600 mg daily	No significant change	Decreased rilpivirine effects	Red: Avoid combination	Do not coadminister: Reduced levels of rilpivirine	Use alternative agents
6959	Rilpivirine Esomeprazole 123	Rilpivirine			Esomeprazole			Decreased rilpivirine effects	Red: Avoid combination	Do not coadminister: Reduced levels of rilpivirine	Contraindicated. Use alternative agents.	H2-antagonists if administered at least 12 hours before rilpivirine or at least 4 hours after rilpivirine.	DHHS Adult ARV Guidelines
6264	Rilpivirine DTG 649	Rilpivirine	25 mg daily	Rilpivirine Cmin increased 21%	Dolutegravir	50 mg daily	Dolutegravir Cmin increased 22%		Green: Administer standard doses	Administer standard doses
6280	Rilpivirine RFB 665	Rilpivirine	150 mg daily	Rilpivirine AUC decreased 46%; Cmin decreased 49%; Cmax decreased 35%	Rifabutin	300 mg daily		Decreased rilpivirine effects	Red: Avoid combination	Do not coadminister: Reduced levels of rilpivirine	Use alternative agents
6265	Rilpivirine Ethinyl estradiol / Norethindrone acetate 650	Rilpivirine	25 mg daily	No significant change	Ethinyl estradiol / Norethindrone acetate	0.035 mg daily ethinyl estradiol with 1 mg norethindrone daily	Ethinyl estradiol Cmax increased 17%; Norethindrone: no significant change		Green: Administer standard doses	Administer standard doses
6266	Rilpivirine Simeprevir 651	Rilpivirine	25 mg daily x 11 days	Rilpivirine Cmin increased 25%	Simeprevir	150 mg daily x 11 days	No significant change		Green: Administer standard doses	Administer standard doses
6267	Rilpivirine Sildenafil 652	Rilpivirine	75 mg daily	No significant change	Sildenafil	50 mg x 1	No significant change		Green: Administer standard doses	Administer standard doses
6268	Rilpivirine Chlorzoxazone 653	Rilpivirine	150 mg daily	Rilpivirine AUC increased 25%; Cmin increased 18%; Cmax increased 17%	Chlorzoxazone	500 mg x 1	No significant change		Green: Administer standard doses	Administer standard doses
6269	Rilpivirine SOF 654	Rilpivirine	25 mg daily		Sofosbuvir	400 mg x 1	Sofosbuvir Cmax increased 21%		Green: Administer standard doses	Administer standard doses
6270	Rilpivirine Famotidine 655	Rilpivirine	150 mg x 1	No significant change	Famotidine	40 mg x 1 taken 12 hours before rilpivirine			Green: Administer standard doses	Administer standard doses
6271	Rilpivirine Famotidine 656	Rilpivirine	150 mg x 1	Rilpivirine Cmax increased 21%	Famotidine	40 mg x 1 taken 4 hours after rilpivirine			Green: Administer standard doses	Administer standard doses